In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRISPR Therapeutics AG

www.crisprtx.com

Latest From CRISPR Therapeutics AG

Start-Up Quarterly Statistics: Financings Fell 17% To $2.84bn In Q2

A review of second quarter biopharma start-up deal-making and financing activity from Strategic Transactions showed a quarter-over-quarter drop in dollars raised despite multiple mega-rounds, including $100m-plus VC deals for SpringWorks and Fusion.

Deals Financing

Versant's Century Aims For Off-The-Shelf Cancer Cell Therapies

With Bayer’s venture arm providing $215m, Versant Ventures’ Century Therapeutics emerges with $250m and a plan to develop allogeneic stem cell therapies for various cancers, including solid tumors.

ImmunoOncology Business Strategies

If PTAB Backs Berkeley IP Holders' New Patent Claims, CRISPR Licensing Could Be Simplified

The USPTO's PTAB will determine whether UC-Berkeley or Broad Institute holders of CRISPR patents first invented its use in eukaryotic cells. The outcome could either benefit the Berkeley group, which could simplify licensing deals, or maintain the status quo.

Intellectual Property Business Strategies

ERS Genomics Completes 45 CRISPR Licensing Deals To Date, Largely For Screening, Discovery

Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.

Deals Intellectual Property
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • CRISPR Therapeutics AG
  • Senior Management
  • Samarth Kulkarni, PhD, CEO
    Michael Tomsicek, CFO
    Rodger Novak, PhD, Pres.
    Lawrence Klein, PhD, Head, Bus. Dev. & Strategy
    Tony Ho, MD, Head, R&D
  • Contact Info
  • CRISPR Therapeutics AG
    Phone: 41 561 32 77
    Baarerstrasse 14
    Zug, V8 CH-6300
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register